In brief: changes at Psiron, ATPi, Cytopia, Epitan
Monday, 04 April, 2005
Psiron (ASX:PSX) has announced that Stephen Jones will assume day-to-day control of the company, taking on the role of executive chairman. Julie Nutting will continue as the company's chief executive with responsibility for five clinical trial and manufacturing milestones for the company's CVA 21 virus by the end of the year.
Sydney-based technology incubator ATP Innovations has appointed former NSW state government bureaucrat Hamish Hawthorn as director of life sciences and technology commercialisation. Until recently, Hawthorn was part of the NSW Department of State and Regional Development team that managed the state's BioFirst strategy.
Cytopia (ASX:CYT) has appointed mergers and acquisitions specialist Rod Lyle as a non-executive director. As a partner at Melbourne law firm Deacons, Lyle was involved in the spin-off of Avexa from Amrad, and advised Genepharm Australasia on its IPO.
Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has appointed former Peptech chief executive Roger Aston as a non-executive director. Aston is currently an executive director of Australian Cancer Technology and a director of Psivida.
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
